Opening book details…
Can I read Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease on EtoBox?
Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease by Carl Eriksson; Jonas Söderling; Sara Karlqvist; Gabriella Bröms; Åsa H. Everhov; Daniel Bergemalm; Jonas F. Ludvigsson; Ola Olén; Jonas Halfvarson; The SWIBREG study group is a Medicine article available to read on EtoBox.
What is Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease about?
## Background There are little data on positioning biologics in Crohn's disease (CD). ## Aims We aimed to assess the comparative effectiveness and safety of ustekinumab vs tumour necrosis factor-alpha (anti-TNF) agents after first-line treatment with anti-TNF in CD. ## Methods We used Swedish nationwide registers to identify patients with CD, exposed to anti-TNF who initiated second-line biologic treatment with ustekinumab or second-line anti-TNF therapy. Nearest neighbour 1:1 propensity score matching (PSM) was used to balance the groups. The primary outcome was 3-year drug survival used as a proxy for effectiveness. Secondary outcomes included drug survival without hospital admission, CD-related surgery, antibiotics, hospitalization due to infection and exposure to corticosteroids. ## Results Some 312 patients remained after PSM. Drug survival at 3 years was 35% (95% CI 26–44%) in ustekinumab compared to 36% (95% CI 28–44%) in anti-TNF-treated patients (p = 0.72). No statistically significant differences were observed between the groups in 3-year survival without hospital admission (72% vs 70%, p = 0.99), surgery (87% vs 92%, p = 0.17), hospital admission due to infection (92% vs
Who reads Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Carl Eriksson; Jonas Söderling; Sara Karlqvist; Gabriella Bröms; Åsa H. Everhov; Daniel Bergemalm; Jonas F. Ludvigsson; Ola Olén; Jonas Halfvarson; The SWIBREG study group
- Publisher
- Springer Science and Business Media LLC
- Published
- 2023
- Language
- EN
- Field
- Medicine (Health Sciences)